Recursion Pharmaceuticals, Inc. RXRX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s EPS (basic)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported EPS (basic) of -$0.22 in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s EPS (basic) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s EPS (basic) increased by 56.0% year-over-year, from -$0.50 to -$0.22.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s EPS (basic) has grown at a -11.1% compound annual growth rate (CAGR), from -$2.31 to -$1.44.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.